Elena H. Ridloff's most recent trade in Sionna Therapeutics Inc. was a trade of 34,500 Common Stock done at an average price of $21.1 . Disclosure was reported to the exchange on Aug. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sionna Therapeutics Inc. | Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 21.08 per share. | 19 Aug 2025 | 34,500 | 89,032 | - | 21.1 | 727,260 | Common Stock |
| Sionna Therapeutics Inc. | Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 22.69 per share. | 19 Aug 2025 | 17,500 | 71,532 | - | 22.7 | 397,075 | Common Stock |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Elena H. Ridloff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 34,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Elena H. Ridloff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 26,871 | 0 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Elena H. Ridloff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 25,879 | 0 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Elena H. Ridloff | Director | 20 Jun 2025 | 25,296 | 0 | - | 0.6 | 14,419 | Common Stock | |
| Kronos Bio Inc | Elena H. Ridloff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 17,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Elena H. Ridloff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 17,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Elena H. Ridloff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 15,450 | 0 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2025 | 4,500 | 4,500 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 11 Jun 2025 | 4,500 | 0 | - | 50 | 225,000 | Common Stock |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.29 per share. | 11 Jun 2025 | 4,500 | 4,500 | - | 20.3 | 91,305 | Common Stock |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.67 per share. | 03 Jun 2025 | 12,000 | 12,000 | - | 27.7 | 332,040 | Common Stock |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Sale of securities on an exchange or to another person at price $ 45.50 per share. | 03 Jun 2025 | 7,200 | 4,800 | - | 45.5 | 327,600 | Common Stock |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Sale of securities on an exchange or to another person at price $ 47.00 per share. | 03 Jun 2025 | 4,800 | 0 | - | 47 | 225,600 | Common Stock |
| Sionna Therapeutics Inc. | Elena H. Ridloff | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 157,820 | 157,820 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Elena H. Ridloff | Director | 25 Jun 2024 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | ||
| Kronos Bio Inc | Elena H. Ridloff | Director | 25 Jun 2024 | 11,333 | 25,296 | - | 0 | Common Stock | ||
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Elena H. Ridloff | Director | 22 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | ||
| Kronos Bio Inc | Elena H. Ridloff | Director | 22 Jun 2023 | 11,333 | 13,963 | - | 0 | Common Stock | ||
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Elena H. Ridloff | Director | 22 Jun 2022 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | ||
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,063 | 20,063 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Elena H. Ridloff | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 3,245 | 11,585 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Elena H. Ridloff | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 3,245 | 6,491 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Elena H. Ridloff | EVP and CFO | Sale of securities on an exchange or to another person at price $ 20.33 per share. | 29 Apr 2021 | 1,032 | 10,553 (0%) | 0% | 20.3 | 20,981 | Common Stock |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 40,127 | 40,127 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Elena H. Ridloff | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 36,231 | 36,231 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Elena H. Ridloff | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 9,839 | 9,839 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Elena H. Ridloff | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 6,490 | 10,391 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Elena H. Ridloff | EVP and CFO | Sale of securities on an exchange or to another person at price $ 50.61 per share. | 04 Feb 2021 | 2,051 | 8,340 (0%) | 0% | 50.6 | 103,801 | Common Stock |
| Acadia Pharmaceuticals Inc | Elena H. Ridloff | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2021 | 2,722 | 4,917 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Elena H. Ridloff | EVP and CFO | Sale of securities on an exchange or to another person at price $ 53.34 per share. | 06 Jan 2021 | 1,016 | 3,901 (0%) | 0% | 53.3 | 54,193 | Common Stock |
| Acadia Pharmaceuticals Inc | Elena H. Ridloff | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2021 | 1,016 | 9,873 | - | - | Restricted Stock Units |